Company Overview and News

83
Market Live: Nifty volatile, Auto index outperforms; Infosys, HDFC twins dip

2018-06-18 moneycontrol
Shriram Mutual Fund has revised the exit load structure of Shriram Equity and Debt Opportunities Fund with immediate effect, the fund house said in an addendum.
539150 ADANIENT 532617 532538 ICLQY 531349 PNCINFRA 512599 TTNQY 532343 532662 500470 532540 UCLQY CELG YESBANK INDIGO PANACEABIO CELGZ HINDALCO ANNRY TVSMOTOR IBN HTMEDIA JETAIRWAYS UCLQF 532648 YYBKY 532822 ULTRACEMCO 539448 HNDNF ICICIBANK TTST TATASTEEL TATLY 532174 IDEA TCS DCMSHRIRAM 500440 523367

83
Market Live: Midcap underperforms Nifty; ICICI Bank top gainer on Sensex

2018-06-18 moneycontrol
Market sentiment was being dominated by trade tensions between the U.S. and China with new tariffs on the table. More than 800 Chinese goods are due to get an extra 25 percent tariff starting on July 6. As a result, China has responded with a 25 percent tariff that will also be applied to certain US products starting on the same day, reports CNBC.
539150 ADANIENT 532617 532538 ICLQY 531349 PNCINFRA 512599 TTNQY 532343 532662 500470 532540 UCLQY CELG YESBANK INDIGO PANACEABIO CELGZ HINDALCO ANNRY TVSMOTOR IBN HTMEDIA JETAIRWAYS UCLQF 532648 YYBKY 532822 ULTRACEMCO 539448 HNDNF ICICIBANK TTST TATASTEEL TATLY 532174 IDEA TCS DCMSHRIRAM 500440 523367

0
Panacea Biotec stock jumps 6% on settlement agreement with Celgene for Abraxane generic

2018-06-18 moneycontrol
Panacea Biotec share price gained 5.6 percent intraday on Monday after the company settled disputes with Celgene for Abraxane generic.
PANACEABIO 531349

56
Panacea settles patent dispute with US-based Celgene Corp

2018-06-15 livemint
New Delhi:Drug firm Panacea Biotec along with its partner Apotex has inked a pact with US-based Celgene Corporation to settle patent disputes regarding Abraxane, a drug used to treat various kinds of cancer including that of breast and lungs.
PANACEABIO CELGZ CELG 531349

0
Panacea Biotec Limited - Financial Result Updates

2018-05-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PANACEABIO 531349

0
Panacea Biotec Limited - Outcome of Board Meeting

2018-05-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PANACEABIO 531349

0
Panacea Biotec Limited - Disclosure under SEBI Takeover Regulations

2018-04-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PANACEABIO 531349

0
Serum Institute Of India sells 31.57 lakh shares of Panacea Biotec

2018-03-27 moneycontrol
On March 26, 2018 Adar Cyrus Poonawalla bought 31,57,900 shares of Panacea Biotec at Rs 285.
PANACEABIO 531349

0
Panacea Biotec Limited - Disclosure under SEBI Takeover Regulations

2018-03-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PANACEABIO 531349

0
Panacea Biotec Limited - Outcome of Board Meeting

2018-03-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PANACEABIO 531349

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...